Guerbet strengthens its Executive Committee with the appointment of Charlotte Bamière, General Counsel
06 Avril 2022 - 08:30AM
Guerbet strengthens its Executive Committee with the appointment of
Charlotte Bamière, General Counsel
Guerbet
strengthens its Executive Committee with the appointment of
Charlotte Bamière, General Counsel
Villepinte,
April 6, 2022 – Guerbet (FR0000032526 GBT), a
global specialist in contrast agents and medical imaging solutions,
has announced the appointment of Charlotte Bamière, General
Counsel, to the Executive Committee.
Charlotte
Bamière has contributed to the development of Guerbet’s
legal function since joining the Group in 2011. In 2015, Charlotte
Bamière and her team played a crucial part in securing the
acquisition and integration of Mallinckrodt’s contrast media and
delivery systems (CMDS) business.
“Charlotte serves a
pivotal role in rolling out the Group’s strategy, in terms of both
developing Guerbet’s distribution model in Asia and securing
external growth,” said David Hale, Chief Executive Officer of
Guerbet.
With this promotion, Guerbet confirms
CEO David Hale’s commitment to increase gender parity within the
Group, particularly in its management bodies.
Charlotte
Bamière holds a master’s degree in business law and
taxation from the University of Paris Panthéon-Assas, a double
postgraduate degree in foreign trade law and international
arbitration from the University of Paris Panthéon-Sorbonne, and an
MBA in business administration from the IAE Paris Sorbonne Business
School. She began her career in 2001 in the United States in market
finance at FIMAT USA (Société Générale). She then moved into
long-term automobile rental at LeasePlan, before finally joining
SNPE. This experience in fine chemicals, working for a
pharmaceutical industry subcontractor, led her to Guerbet, which
she joined in 2011. She rose to the post of General Counsel in
2016.
About GuerbetAt
Guerbet, we build lasting relationships so that we enable people to
live better. That is our purpose. We are a global leader in medical
imaging, offering a comprehensive range of pharmaceutical products,
medical devices, and digital and AI solutions for diagnostic and
interventional imaging. As pioneers in contrast products for 95
years, with more than 2,600 employees worldwide, we continuously
innovate and devote 8%-10% of our revenue to research and
development in five centers in France, Israel, and the United
States. Guerbet (GBT) is listed on Euronext Paris (segment B – mid
caps) and generated €732 million in revenue in 2021. For more
information, please visit www.guerbet.com.
Media
relations
Guerbet
GlobalACTIFIN – Mathias Jordan+33 (0)1 56 88 11 26 /
mjordan@actifin.fr
- PR-Guerbet strengthens its Executive Committee with the
appointment of Charlotte Bamière
Guerbet (EU:GBT)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Guerbet (EU:GBT)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024